C-Peptide ELISA Kit

Produktnummer ABIN1326822

Produktdetails C-Peptide ELISA Kit

Target: C-Peptide

Reaktivität: Human

Nachweismethode: Colorimetric

Methodentyp: Competition ELISA

Applikation: ELISA

Verwendungszweck: The C-Peptide Elisa Kit is based on the competition principle and the microplate separation. An unknown amount of C-Peptide present in the sample and a fixed amount of C-Peptide Conjugate compete for the binding sites of a polyclonal C-Peptide antiserum coated onto the wells. In a second step an Enzyme Complex binds to C-Peptide Conjugate. The unbound Enzyme Complex is washed off. Having added the Substrate Solution, the concentration of C-Peptide in the samples is inversely proportional to the optical density measured.

Analytische Methode: Quantitative

Anwendungsinformationen

Plattentyp: Pre-coated

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Lagerung: 4 °C

Referenzen für C-Peptide ELISA Kit (ABIN1326822)

Pickens, Sordillo, Comstock, Harris, Hortos, Kovan, Fenton: "Plasma phospholipids, non-esterified plasma polyunsaturated fatty acids and oxylipids are associated with BMI." in: Prostaglandins, leukotrienes, and essential fatty acids, Vol. 95, pp. 31-40, (2015) (PubMed).

Chang, Cai, Huang, Cheng, Chueh, Hsu: "Adaptive human CDKAL1 variants underlie hormonal response variations at the enteroinsular axis." in: PLoS ONE, Vol. 9, Issue 9, pp. e105410, (2014) (PubMed).

Comstock, Lewis, Pathak, Hortos, Kovan, Fenton: "Cross-sectional analysis of obesity and serum analytes in males identifies sRAGE as a novel biomarker inversely associated with diverticulosis." in: PLoS ONE, Vol. 9, Issue 4, pp. e95232, (2014) (PubMed).

Details zu C-Peptide

Target: C-Peptide

Abstract: C-Peptide Produkte

Synonyme: insulin 2 ELISA Kit, Ins2 ELISA Kit

Hintergrund: Human C-Peptide has a molecular mass of approximately 3000 daltons. C-Peptide has no metabolic function. However, since C-Peptide and insulin are secreted in equimolar amounts, the immunoassay of C-Peptide permits the quantitation of insulin secretion. This is the reason for the clinical interest of serum and urinary determinations of C-Peptide. Moreover, C-Peptide measurement has several advantages over immunoassays of insulin.The half-life of C-Peptide in the circulation is between two and five times longer than that of insulin. Therefore, C-Peptide levels are a more stable indicator of insulin secretion than the more rapidly changing levels of insulin. A very clear practical advantage of C-Peptide measurement arising from its relative metabolic inertness as compared to insulin is that C-Peptide levels in peripheral venous blood are about 5-6 times greater than insulin levels. Also, relative to an insulin assay, the C-Peptide assay's advantage is its ability to distinguish endogenous from injected insulin. C-Peptide has also been measured as an additional means for evaluating glucose tolerance and glibenclamide glucose tests.C-Peptide levels are in many ways a better measurement of endogenous insulin secretion than peripheral insulin levels. C-Peptide may be measured in either blood or urine. With improved sensitive C-Peptide immunoassays, it is now possible to measure C-Peptide values at extremely low levels. The clinical indications for C-Peptide measurement include diagnosis of insulinoma and differentiation from factitious hypoglycemia, follow-up of pancreatectomy, and evaluation of viability of islet cell transplants. Recently, these indications have been dramatically expanded to permit evaluation of insulin dependence in maturity onset diabetes mellitus.